A diversified clinical-stage pipeline is advancing with strong institutional backing and cash runway into FY28. Lead asset amsulostat shows promising efficacy and safety in myelofibrosis, with expansion into MDS and neurodegenerative diseases, and multiple near-term clinical catalysts expected.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.